Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.54 |
| ▸ | MAOA | P21397 | 7/20 | 0.54 |
| ▸ | KDM1A | O60341 | 12/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067375 | 0.80 | MAOB (0.52) | MAOBMAOAKDM1ARCOR1SLC6A3 | |
| SCHEMBL6425355 | 0.79 | MAOB (0.57) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL6425356 | 0.79 | MAOB (0.57) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL13598563 | 0.76 | MAOB (0.52) | MAOBMAOAKDM1ARCOR1SLC6A3 | |
| SCHEMBL6428000 | 0.75 | MAOB (0.59) | MAOBMAOAKDM1ASLC6A3 | |
| SCHEMBL83035 | 0.71 | HSD11B1 (0.51) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL3054516 | 0.71 | MAOB (0.42) | MAOBMAOAKDM1ARCOR1SLC6A3 | |
| SCHEMBL56590 | 0.69 | MAOB (0.48) | MAOBMAOASLC6A3 | |
| SCHEMBL23001568 | 0.67 | MAOB (0.39) | MAOBMAOASLC6A3 | |
| SCHEMBL21564625 | 0.67 | MAOB (0.57) | MAOBMAOAKDM1ARCOR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2022-09-08 | — | — | US | disclosed |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2022-06-07 | — | — | US | disclosed |
| CN-109153636-B | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | 朱比连特埃皮科尔有限责任公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC | 2020-10-01 | — | — | US | disclosed |
| EP-3455204-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Biosys Ltd. (IN) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017195216-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-11-16 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308110-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | MAOB 58/4885MAOA 53/4885KDM1A 13/4885 |
| US-11352322-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | MAOB 58/4885MAOA 53/4885KDM1A 13/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | MAOB 45/4885MAOA 41/4885KDM1A 15/4885 |
| US-20220281815-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | MAOB 45/4885MAOA 41/4885KDM1A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.